The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $231,700 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to Texas A&M University System Health Science Center to develop biologics capable of inhibiting Staphylococcus aureus (S. aureus) infection. The project aims to characterize the binding properties and neutralization capacity of engineered DARPin proteins against a panel of S. aureus isolates, generate additional DARPin proteins with broad reactivity against S. aureus, and evaluate the protective efficacy of the DARPin proteins in a murine sepsis model. Successful completion of this research is expected to yield novel therapeutic candidates for treating S. aureus infections, including antibiotic-resistant strains such as methicillin-resistant S. aureus (MRSA). The project period runs from January 2025 through December 2026.
Generated 3/4/25, 5:30 AM